Literature DB >> 8243590

Studies on the epidemiology of child infections in the Bari area (south Italy). VII. Epidemiology of Epstein-Barr virus infections.

G Leogrande1, E Jirillo.   

Abstract

Serological patterns against Epstein-Barr virus (EBV) specific antigens were determined in 3732 healthy babies and children aged 0-10 years living in the Bari area (South Italy). IgG antibodies against EBV capsid antigen (VCA) were found in 2713 subjects (72.7%). Seropositivity rates, high in the first semester of life (83.8%), declined between 6 and 12 months (65.6%) and even further between 1 and 2 years (43.8%). After 2 years the frequency of positive children rose progressively reaching steady levels between 5 and 7 years (80.2%) and between 8 and 10 years (81.9%). IgA antibodies against VCA, IgG anti-early viral antigen (EA) and IgG against virus-associated nuclear antigens (EBNA) were found in 17.9%, 15.9% and 25.7% of the subjects tested, respectively. IgM anti-VCA were found only in 35 (0.9%) children, but 818 (21.9%) exhibited antibody patterns suggestive of a recent infection: IgG anti-VCA > or = 1:160 alone or in association with IgA anti-VCA or IgG anti-EA or both. These results suggest that in this area the primary infection by EBV occur early in life, with immunity to EBV acquired primarily after 4 years.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243590     DOI: 10.1007/bf00157392

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  16 in total

1.  Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis.

Authors:  J Nikoskelainen; E U Neel; D A Stevens
Journal:  J Clin Microbiol       Date:  1979-07       Impact factor: 5.948

2.  Seroepidemiologic study of Epstein-Barr virus infections in a rural community.

Authors:  C V Sumaya; W Henle; G Henle; M H Smith; D LeBlanc
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

3.  LPS-mediated triggering of T lymphocytes in immune response against gram-negative bacteria.

Authors:  E Jirillo; C De Simone; V Covelli; H Kiyono; J R McGhee; S Antonaci
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

4.  The seroepidemiology of infection due to Epstein-Barr virus in southern India.

Authors:  A R Venkitaraman; G M Lenoir; T J John
Journal:  J Med Virol       Date:  1985-01       Impact factor: 2.327

5.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

6.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  Development of immunity to Epstein-Barr virus in Malaysian children.

Authors:  M S Yadav; N Malliga; D V Ablashi
Journal:  Microbiologica       Date:  1987-01

9.  Prevalence of antibodies to Epstein-Barr virus and cytomegalovirus in sera from a group of children in the People's Republic of China.

Authors:  P S Wang; A S Evans
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

10.  The role of lipoproteins in EBV early antigen induction in Raji cells.

Authors:  M Simon; I Melzner; B Bültmann
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

View more
  2 in total

1.  Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.

Authors:  Shizuko Harada; Yoshio Kamata; Yasuyuki Ishii; Hiroyuki Eda; Ryo Kitamura; Maya Obayashi; Sayuri Ito; Fumihiko Ban; Jun Kuranari; Haruhiko Nakajima; Tomoko Kuze; Masao Hayashi; Nobuhiko Okabe; Hidenobu Senpuku; Nobuyuki Miyasaka; Yoshiko Nakamura; Hirokazu Kanegane; Kazuo Yanagi
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study.

Authors:  Erica Franceschini; Jessica Plessi; Stefano Zona; Antonella Santoro; Margherita Digaetano; Francesco Fontana; Gaetano Alfano; Giovanni Guaraldi; Patrizia Comoli; Francesca Facchini; Leonardo Potenza; William Gennari; Mauro Codeluppi; Mario Luppi; Gianni Cappelli; Inge C Gyssens; Cristina Mussini
Journal:  Transplant Direct       Date:  2017-06-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.